Cellectis Reports Third Quarter 2026 Financial Results and Provides a Business Update

Cellectis faces deepening losses and delayed clinical milestones despite ample cash reserves.

What the company is saying

Cellectis presents itself as fully committed to a strategic transformation, shifting focus to in vivo gene editing with .HEAL-101 and .HEAL-201 as flagship programs. CEO André Choulika highlights preclinical data for .HEAL-101, including up to 70% APOC3 editing and 76% triglyceride reduction in disease models, and confirms a Phase 1 trial in China remains on track for first data in the second half of 2027. The company details the discontinuation of lasme-cel and eti-cel, with enrollment stopped and site close-outs underway, and expects a global headcount reduction of up to 70% through 2027, pending regulatory processes. Partnerships with AstraZeneca, Servier/Allogene, and Iovance are referenced, but only as ongoing or enrolling, without new quantitative milestones. Management attributes the $47.5 million revenue decline mainly to reduced activity under the AstraZeneca agreement and explains the $39.7 million R&D expense increase as driven by a $34.9 million transformation impact, including a $26.6 million impairment. The narrative is factual, acknowledges restructuring pain, and claims sufficient cash to fund operations into the second half of 2028.

What the data suggests

Financial results show a sharp deterioration: revenues and other income fell from $67.4 million to $19.9 million for the nine months ended September 30, 2026, mainly due to lower AstraZeneca collaboration activity. R&D expenses rose to $108.8 million, up $39.7 million year-over-year, with $34.9 million attributable to transformation costs, including a $26.6 million impairment, $6.2 million in termination benefits, and $2.1 million in close-out costs. SG&A expenses increased to $17.5 million, with $1.1 million from restructuring. Net loss attributable to shareholders more than doubled to $101.1 million ($1.00 per share), driven by a $90.5 million increase in operating loss, partially offset by a $30.8 million swing to a $5.2 million net financial gain. Cash, cash equivalents, and deposits declined by $62 million to $149 million, with major outflows to suppliers ($37.9 million) and payroll ($37.5 million), partially offset by $21.4 million in customer receipts and $5.4 million in interest. The company expects existing cash to last into the second half of 2028. Pipeline progress remains preclinical, with first clinical data for .HEAL-101 not expected until late 2027 and for .HEAL-201 until 2028. Partnership updates lack quantitative progress or near-term catalysts.

Analysis

The announcement is measured in tone and provides detailed, transparent financial and operational disclosures. The majority of key claims are realised facts, including cash position, revenue, expenses, and net loss, all of which show a deteriorating financial position with sharply lower revenues and higher losses. Forward-looking statements, such as the initiation of clinical trials and expected headcount reductions, are clearly identified and not overstated. The company is incurring significant R&D and restructuring costs now, while the potential benefits from its pipeline (notably .HEAL-101 and .HEAL-201) are long-dated, with first clinical data not expected until 2027–2028. There is no narrative inflation or exaggerated language; if anything, the tone is factual and acknowledges program discontinuations and cost-cutting. The gap between narrative and evidence is minimal, but the underlying signal is weak negative due to worsening financials and delayed pipeline catalysts.

Risk flags

• ●The company is incurring high operating losses, with net loss attributable to shareholders rising to $101.1 million for the nine months ended September 30, 2026, more than double the prior year. This level of loss, if sustained, could erode cash reserves faster than projected, especially if restructuring or R&D costs exceed expectations.
• ●Revenue has collapsed, falling by $47.5 million year-over-year to $19.9 million, mainly due to reduced AstraZeneca collaboration activity. Without new or expanded partnerships, there is no clear path to replace this lost revenue in the near term.
• ●The pipeline is at a preclinical or early clinical stage, with first human data for .HEAL-101 not expected until late 2027 and for .HEAL-201 until 2028. This long execution gap exposes the company to substantial clinical, regulatory, and competitive risks before any potential value realization.
• ●A planned headcount reduction of up to 70% over two years introduces operational risk, as rapid downsizing can disrupt institutional knowledge, project continuity, and morale, especially if not carefully managed through regulatory processes in France and the U.S.
• ●Partnerships with AstraZeneca, Servier/Allogene, and Iovance are referenced but lack new quantitative milestones or financial commitments, raising uncertainty about the timing and scale of any future revenue contributions from these collaborations.

Bottom line

Cellectis is undergoing a costly and disruptive transformation, with sharply lower revenues, surging losses, and a pipeline that remains preclinical or early-stage. The company’s cash position of $149 million provides a multi-year runway, but with net losses exceeding $100 million in nine months and no near-term revenue catalysts, financial risk remains elevated. The earliest potential value inflection—preliminary .HEAL-101 clinical data in China—is not expected until the second half of 2027, leaving investors facing a prolonged period without clinical or commercial validation. Partnerships are ongoing but provide no immediate relief or new milestones. The most important takeaway is that Cellectis is a high-risk, long-duration story: investors must be prepared for continued losses and delayed catalysts, with the company’s future hinging on the eventual success of its in vivo gene editing programs.

Announcement summary

(NASDAQ:CLLS) Cellectis reported financial results for the third quarter of 2026 and provided a business update. As of September 30, 2026, Cellectis had $149 million in consolidated cash, cash equivalents, restricted cash, and fixed-term deposits classified as current and non-current financial assets. Restricted cash totaled $2.3 million, and fixed-term deposits were $118.3 million as of the same date. The company is focusing on its in vivo gene editing pipeline, with .HEAL-101 achieving up to 70% APOC3 gene editing in a humanized liver model and reducing triglycerides by 76% in a disease model after a single administration. The initiation of a Phase 1 investigator-initiated trial for .HEAL-101 in China is on track, with first clinical data expected in the second half of 2027. .HEAL-201 demonstrated more than 90% reduction in mean plasma PCSK9 levels in a liver-humanized mouse model, with a Phase 1 IIT in China planned and preliminary clinical data expected in the first half of 2028. Cellectis is discontinuing the lasme-cel and eti-cel clinical programs, with enrollment stopped and site close-out activities underway. The company expects its global headcount to be reduced by up to 70% from pre-transition levels over 2026 and 2027, subject to French works council consultation and compliance with French and U.S. labor laws. Under its partnership with AstraZeneca, activities continue to develop up to 10 novel cell and gene therapy products. Allogene announced that cema-cel is being evaluated in the ALPHA3 pivotal trial in LBCL, with the next clinical update anticipated in mid-2027 and trial enrollment expected to complete by year-end 2027. Iovance is enrolling patients in a Phase 1/2 trial of IOV-4001 for metastatic melanoma and mNSCLC. As of September 30, 2026, Cellectis' cash position decreased by $62 million from $211 million at December 31, 2025, primarily due to payments to suppliers of $37.9 million, payroll-related payments of $37.5 million, lease liability payments of $7.3 million, repayments of $4.0 million under the PGE loan, and capital expenditures of $1.9 million, partially offset by $21.4 million of cash received from customers and $5.4 million of interest received. Consolidated revenues and other income were $19.9 million for the nine months ended September 30, 2026, compared to $67.4 million for the same period in 2025, a decrease of $47.5 million mainly due to lower activity under the AstraZeneca agreement. R&D expenses were $108.8 million for the nine months ended September 30, 2026, up from $69.1 million in 2025, with a $34.9 million impact from the strategic transformation, including a $26.6 million one-off impairment loss, $6.2 million of termination benefits, and $2.1 million of close-out costs for lasme-cel and eti-cel. SG&A expenses were $17.5 million for the nine months ended September 30, 2026, compared to $15.0 million in 2025, with a $1.1 million impact from the transformation, including $0.9 million of termination benefits and a $0.3 million impairment loss. The consolidated net financial gain for the nine months ended September 30, 2026 was $5.2 million, compared to a $25.6 million net financial loss in 2025, reflecting a $10.8 million increase in financial income and a $20.0 million decrease in financial expenses. Net loss attributable to shareholders was $101.1 million (or $1.00 per share) for the nine months ended September 30, 2026, compared to $41.3 million (or $0.41 per share) in 2025. Adjusted net loss attributable to shareholders was $95.2 million (or $0.95 per share) for the nine months ended September 30, 2026, compared to $37.4 million (or $0.37 per share) in 2025. The company believes its existing cash and equivalents, together with fixed-term deposits, will be sufficient to fund operations into the second half of 2028.

Disagree with this article?